Moraal B, Pohl C, Uitdehaag BM et al.
Multiple Sclerosis Center Amsterdam, Vrije University, Amsterdam, The Netherlands.
Arch Neurol 2009;66:1345–52.
Editor’s note: The early phase of multiple sclerosis (MS), including conversion of a clinically isolated syndrome (CIS) to clinically definite MS, remains the focus of a number of recent clinical studies. The BENEFIT (Betaferon/Betaseron in Newly Emerging MS for Initial Treatment) trial demonstrated that early initiation of disease-modifying therapy with subcutaneous interferon-beta 1b 250 μg after a CIS delayed conversion to clinically definite MS at 3- and 5-year follow-up (
Lancet 2007;370:389–97,
Lancet Neurol 2009;8:987–97, reviewed in this issue of
CML – Multiple Sclerosis 2010;2[1]:13–4).